Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (6835)	7/10/1999 12:28:00 AM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 9719

Vector1: This is the follow-up post with a link to the article in the Baltimore-Sun: Message 10449749 Fauci's opinion is not to be taken lightly. Interesting that Science did not choose to highlight this article too much (of course, given the ratio of submissions to acceptances in Science, the fact that it got published cannot be overlooked -- I am just nit picking). First, it is one of the shorties, and second it does not come with a News & View-type commentary (another immunology article by researchers at Wash U and Stanford gets that honor). The press release really pushed hard (hyped?) when you compare with what actually made it to print in the journal. It is also interesting (and this comes from a brief conversation with a real biologist) that they chose to compare BLyS's action on B-cells with IL-2 (yes, 2), apparently, a lousy B-cell stimulator. BLyS, from the graphs, does a bit worse than IL-2. As for the platform, that's another story, and, for sure, a very impressive one. And late thanks for the excerpt from Alex Brown on CLTR. PB